AlzeCure

As part of the Friends in Science initiative by Flemingsberg Science, we held a lunch seminar where our CEO, Martin Jönsson, and Pontus Forsell, Head of Discovery and Research, discussed AlzeCure's ongoing projects, updates, and the story behind AlzeCure. A huge thank you to all who joined us and to Flemingsberg Science for making this event possible. Learn about us:https://lnkd.in/enfcx4G #Flemingsbergscience #alzecure #campus #science #event

Läs vår bokslutskommuniké för januari – december 2024 Idag publicerar vi bolagets bokslutskommuniké för perioden januari – december 2024, som finns att ta del av på bolagets hemsida: https://lnkd.in/dzFMK2Db ”Fjärde kvartalet 2024 var ytterligare en aktiv och positiv period för AlzeCure Pharma. Under kvartalet publicerade och presenterade vi nya positiva prekliniska resultat från vårt kliniska Alzheimerprojekt NeuroRestore, som vi förbereder för kliniska fas II-studier. Vidare valde vi inom vårt andra Alzheimerprojekt Alzstatin att gå vidare med vår senaste molekyl, ACD680, och förbereda den för kliniska studier. Vi publicerade även nya data inom vårt smärtprojekt mot knäledsartros, TrkA-NAM. I prekliniska modeller visar vi att läkemedelskandidaten ACD137 har minst lika goda smärtlindrande effekter som antikroppen Tanuzemab, samt att ACD137 dessutom har potentiella skyddande effekter. Dessa resultat är mycket lovande och vi är väldigt nöjda med dem” Du hittar PM:et här: https://lnkd.in/gGvRnKbh #AlzeCure #Yearendreport #Alzheimers #Neuropatisksmärta

Read the Year-end report for January – December 2024 from us Today we announce that its Year-end report for the period January – December 2024 Available on the company’s website: https://lnkd.in/eVUtWqNq “The fourth quarter of 2024 was yet another positive and eventful quarter for AlzeCure Pharma. During the quarter, we published and presented new positive preclinical findings from our clinical Alzheimer’s project NeuroRestore, which we are preparing for Phase II clinical studies. Furthermore, in our second Alzheimer’s project, Alzstatin, we opted to advance our latest molecule, ACD680, and prepare it for clinical trials. We also published new data from our pain project targeting knee osteoarthritis, TrkA-NAM. In preclinical models, we have shown that the analgesic effects of the candidate drug ACD137 are at least on par with the antibody Tanuzemab, while also exhibiting potential protective effects. These results are highly promising and we are very pleased with them” Or find it here: https://lnkd.in/gaMEx96F #AlzeCure #Yearendreport #Alzheimers #Neuropathicpain

I intervjun med Redeye delar vd Martin Jönsson sina tankar om den nyligen publicerade artikeln som visar på potentiellt banbrytande insikter om verkningsmekanismen för gammasekretasmodulatorer som Alzstatin ACD680. Se den här: https://lnkd.in/dTjCgcqy

Our CEO, Martin Jönsson, is pleased to announce the EU grant for the Phase 2 clinical trial of NeuroRestore ACD856 targeting Alzheimer’s. A big shoutout to EIC for their support! 😊

Lyssna på intervjun hos Finwire där Martin talar om, det beviljade anslaget och om NeuroRestore, plattformen med fokus på Alzheimers sjukdom. Samt hur anslaget bidrar till validering för bolaget m.m. https://lnkd.in/dYWxCk5C #alzecure #finwire #ACD680 #alzstatin

AlzeCure Pharma med VD Martin Jönsson har som enda svenska biotech-pharma bolag beviljats ett anslag från European Innovation Council (EIC) – en viktig validering av deras banbrytande NeuroRestore-plattform. Vad betyder detta för bolagets finansiering, utveckling och möjligheter att ta ACD856 hela vägen till marknaden? I denna intervju delar AlzeCure med sig av sina insikter och strategier framåt. Missa inte! 🎥 https://lnkd.in/dvWMpchN

New article showing the unique mechanism of action behind Alzstatin as an Alzheimer's treatment Today we announce that a scientific article has been published with novel preclinical data about Alzstatin, the biological effects that could be achieved by the treatment, and the interesting opportunities this brings in the continued development of the drug candidate ACD680.   The published article contains new preclinical data from both cellular model systems and animal models showing that substances in the Alzstatin project, so-called gamma-secretase modulators, reduce the production of toxic amyloid-beta 42 protein (Aβ42), which is the building block of the amyloid plaques found in the brains of Alzheimer's patients.   In addition, the production of shorter Aβ peptides, e.g. Aβ37 and Aβ38, which have been reported to have protective effects and, among other things, can reduce the aggregation of Aβ42, is increased. The results also show that gamma-secretase modulators can stop the growth and reduce the amount of amyloid plaques in the brain in animal models.   Read the press release here: https://lnkd.in/d6nQ-tMn   The article is now available online via the following link: https://lnkd.in/dBRx8N7P #Alzheimers #ACD680 #Alzstatin #alzecure #alzheimerfonden

Our drug candidate ACD440 is a TRPV1 antagonist that is in phase II clinical development, and the company’s aim is to develop a new topical local treatment for neuropathic pain. The drug candidate, which was an important strategic in-licensing carried out in January 2020, fits well into the company’s existing pipeline and strengthens the clinical portfolio. https://lnkd.in/e6CTKT-X #alzecure #neuropathicpain #ACD440 #lifescience

Alzstatin Our disease-modifying research platform Alzstatin consists of gamma-secretase modulators (GSMs). GSMs reduces the production of toxic amyloid beta (Aβ42) in the brain. Aβ42 plays a key pathogenic role in Alzheimer’s disease and begins to accumulate in the brain years before clear symptoms start to develop. Read more here: https://lnkd.in/dt-nNHS #cns #Lifescience #alzehimerfonden #alzstatin #Alzheimers #dementia #alzeCure #GSM #Amyloidbeta